Classified as unfavorable intermediate-, high-, or very high-risk prostate cancer according to NCCN risk stratification guidelines. (Note: cT3a or T3b by MRI or PSMA PET allowed)
Considered by the treating radiation oncologist as a suitable candidate for both HDR brachytherapy boost and SBRT
You may not be if
None
Clareo Health | Radiation Therapy Approaches for People With Prostate Cancer
